lung cancer (metastatic)

     

Select            
Trial Studied trt Control trt patientstagsROB Trial result

ALK inhibitors

alectinib
ALUR, 2018    NCTalectinibchemotherapy2L 2nd line crizotinib failure Exploratory suggesting
ALEX, 2017      NCTalectinibcrizotinib1L 1st line Risk of bias conclusive
ceritinib
ASCEND-4, 2017      NCTceritinibchemotherapy1L 1st line nonsquamous NSCLC Risk of bias suggesting
ASCEND 5, 2017      NCTceritinibpemetrexed or docetaxel2L after crizotinib failure 2nd line crizotinib failure -
crizotinib
Shaw, 2013      NCTcrizotinibchemotherapy2L 2nd line Risk of bias suggesting
PROFILE 1014, 2014        NCTcrizotinibchemotherapy1L 1st line nonsquamous NSCLC Risk of bias suggesting

angiogenesis inhibitors

not classified
Hanna, 2013   -
Heymach, 2008      -
Reck, 2014      NCTDocetaxel plus nintedanib docetaxel plus placebo Low risk of bias -
aflibercept
Ramlau, 2012     Aflibercept and Docetaxel Docetaxel Low risk of bias -
bevacizumab
Reck, 2010     bevacizumab -
Herbst, 2011     bevacizumab + erlotiniberlotinib alone -
Sandler, 2006     bevacizumabplatinum based CT -
Johnson, 2004     bevacizumabplatinum based CT -
Nishio, 2009   bevacizumabplatinum based CT -
Herbst, 2007     bevacizumabplatinum based CT -
ceritinib
Laurie, 2014     cediranib carboplatin and paclitaxel -
Goss, 2010     cediranib carboplatin and paclitaxel -
Dy, 2013     cediranib gemcitabine and carboplatin -
docetaxel
REVEL, 2014      NCTramucirumab + docetaxeldocetaxel aloneLow risk of bias -
motesanib
Scagliottib MONET1, 2012     motesanib plus carboplatin/paclitaxel -
pazopanib
Scagliotti, 2013     pazopanib pemetrexed -
sorafenib
Wakelee, 2012     sorafenib -
Paz-Ares, 2012     sorafenib -
Spigel, 2011     sorafenib and erlotinib erlotinib -
Scagliotti, 2010     sorafenibplacebo -
sunitinib
Groen, 2013     sunitinib erlotinib Low risk of bias -
Scagliottia, 2012     Sunitinib plus erlotinib erlotinib -
Heist CALGB 30704 (Alliance): , 2014     sunitinib pemetrexed -
vandetanib
Aisner, 2013     vandetanib -
Ahn, 2013     vandetanib maintenance -
de Boer, 2011     Vandetanib plus pemetrexed -
Natale, 2009     Vandetanib versus gefitinib Low risk of bias -
Natale, 2011     Vandetanib gefitinib Low risk of bias -
Lee ZEPHYR, 2012     Vandetanib placebo -
Heymach, 2007      vandetanib plus docetaxel placebo plus docetaxel -

CDK (cyclin-dependent kinase) inhibitor

abemaciclib
JUNIPER, 2018      NCTabemacicliberlotinib2nd lineRisk of bias remark

chemotherapy

not classified
Scagliotti (pemetrexed vs bortezomib), 2010     pemetrexedbortezomib -
Scagliotti, 2010     bortezomib and pemetrexedpemetrexednegative
Chiappori, 2010   enzastaurin plus pemetrexedpemetrexednegative
Schiller, 2010   matuzumab plus pemetrexedpemetrexednegative
pemetrexed
Chen, 2008   pemetrexeddocetaxel -
Hanna, 2004     pemetrexeddocetaxel -
Li, 2012     pemetrexeddocetaxel -
Sun, 2013      NCTpemetrexeddocetaxel -
Jose, 2011     pemetrexed plus carboplatindocetaxel plus carboplatin -
Socinski, 2010      NCTpemetrexed plus carboplatindocetaxel plus carboplatin -
Smit, 2009   pemetrexed plus carboplatinpemetrexedsuggesting
vandetanib
De Boer, 2011     vandetanib plus pemetrexedpemetrexednegative

EGFR inhibitors

not classified
SQUIRE    NCT -
INSPIRE    NCT -
afatinib
LUX-LUNG 3, 2015         afatinibcisplatin-based chemotherapy -
LUX-LUNG 6, 2015       afatinibcisplatin-based chemotherapy -
cetuximab
Lynch, 2010     cetuximabCTRisk of bias negative
Butts, 2007     cetuximabCT alone -
FLEX (Pirker), 2009      NCTcetuximab + CTCT alonesuggesting
Rosell, 2008     cetuximab + CTCT alone -
dacomitinib
ARCHER 1050      NCTdacomitinibgefitinib -
erlotinib
OPTIMAL     erlotinibPlatinum-based CT EGFR mutations Risk of bias suggesting
EUTRAC     erlotinibPlatinum-based CT 1st line EGFR mutations Risk of bias suggesting
TITAN       erlotinibPlatinum-based CT 2nd line Risk of bias negative
TRIBUTE (Herbst)     erlotinib + Platinum-based CTPlatinum-based CT 1st line negative
Gatzemeier     erlotinib + Platinum-based CTPlatinum-based CT 1st line negative
Mok     erlotinib + Platinum-based CTPlatinum-based CT 1st line suggesting
SATURN (Cappuzzo)     erlotinib + Platinum-based CTPlatinum-based CT maintenance therapy suggesting
Boutsikou     erlotinib + Platinum-based CTPlatinum-based CT 1st line negative
Lee     erlotinib + Platinum-based CTPlatinum-based CT 2nd line suggesting
Stinchcombe   erlotinib + Platinum-based CTPlatinum-based CTnegative
FASTACT-2 (Wu)     erlotinib + Platinum-based CTPlatinum-based CT 1st line suggesting
gefitinib
West Japan   gefitinib -
Northeast Japan   gefitinib -
CTONG0806 (Yang), 2013   gefitinib -
NEJ002, 2013     gefitinibcarboplatin-paclitaxel1L -
Maemondo, 2010       gefitinibcarboplatin-paclitaxel2L -
IPASS (Mok), 2009      NCTgefitinibcarboplatin-paclitaxel1L -
IPASS           gefitinibcarboplatin/paclitaxel1L -
WJTOG3405 (Mitsudomi), 2010     gefitinibcisplatin plus docetaxel -
WJTOG0203 (Takeda), 2010     gefitinibcontinued platinum-doublet chemotherapy -
ISTANA (Lee), 2010     gefitinibdocetaxel2Lsuggesting
V-15-32 (Maruyama), 2008         gefitinibdocetaxel2Lsuggesting
INTEREST (Kim), 2008   gefitinibdocetaxel2Lnegative
SIGN (Cufer), 2006   gefitinibdocetaxel2Lnegative
IFCT-0301 study (Morère), 2010     gefitinibdocetaxel -
Kris, 2003     gefitinibgefitinib2LLow risk of bias -
First Signal       gefitinibgemcitabine and cisplatin1L -
INTACT 2, 2004     gefitinib paclitaxel and carboplatinpaclitaxel and carboplatin1LLow risk of bias -
NCIC CTG BR19 (Goss), 2013     gefitinibplaceboLow risk of bias -
INFORM; C-TONG 0804, 2012      NCTgefitinibplacebo -
EORTC 08021/ILCP 01/03, 2011      NCTgefitinibplacebo2L -
Goss, 2009     gefitinibplacebo1L -
SWOG S0023 (Kelly), 2008     gefitinibplacebo -
ISEL, 2006       gefitinibplacebo2L -
Tsuboi, 2005     gefitinibplacebo -
INTACT 1.     gefitinib + gemcitabine/cisplatinplacebo + gemcitabine / cisplatin1LLow risk of bias -
INVITE (Crinò), 2008      NCTgefitinibvinorelbine1L -
osimertinib
FLAURA, 2017      NCTosimertinibplacebo1LLow risk of bias suggesting
AURA 3, 2017    NCTosimertinibplatinum-based therapy plus pemetrexed 2Lsuggesting

immune checkpoint inhibition

atezolizumab
IMpower150 (WT), 2018      NCTatezolizumab + bevacizumabbevacizumab (on top platinum-based CT)1L 1st line nonsquamous NSCLC Risk of bias suggesting
IMpower150 (Teff), 2018        NCTatezolizumab + bevacizumabbevacizumab (on top platinum-based CT)1L, Teff 1st line nonsquamous NSCLC Risk of bias suggesting
POPLAR Phase 2 atezolizumab, 2016    NCTatezolizumabdocetaxel2L 2nd+ line platinum failure Risk of bias negative
OAK, 2016      NCTatezolizumabdocetaxel2L 2nd+ line platinum failure Risk of bias suggesting
durvalumab
PACIFIC, 2017      NCTdurvalumabplacebomaintenance maintenance therapy Low risk of bias conclusive
ARCTIC PD-L1 negative, 2018    NCTdurvalumab + tremelimumabStandard of Care3L, PD-L1 negative -
ipilimumab
Reck, 2016      NCTipilimumab + chemotherapyplacebo + chemotherapySCLCLow risk of bias -
Govindan, 2017      NCTipilimumab + chemotherapyplacebo + chemotherapy1LLow risk of bias negative
phase 2 (phased ipilimumab), 2012     ipilimumab + chemotherapyplacebo + chemotherapyLow risk of bias -
nivolumab
CheckMate 057, 2015      NCTnivolumabdocetaxel2L, non squamous 2nd+ line nonsquamous NSCLC Risk of bias suggesting
CheckMate 017, 2015    NCTnivolumabdocetaxel2L, squamous 2nd+ line squamous NSCLC Risk of bias suggesting
CheckMate 026, 2016    NCTnivolumabplatinum-based CT1L, PDL1 positive 1st line PD-L1 positive Risk of bias negative
CheckMate 227 (nivolumab + CT), 2018    NCTnivolumab + CTplatinum-based CT1L, PDL1 negatif 1st line PD-L1 negatif suggesting
CheckMate 227 (High Tumor Mutational Burden), 2018      NCTnivolumab + ipilimumabplatinum-based CT1L, hi TMB 1st line Risk of bias suggesting
pembrolizumab
Keynote 010 10mg, 2015      NCTpembrolizumab 10mgdocetaxel2L, PD-L1 positive 2nd+ line Risk of bias suggesting
Keynote 010 2mg, 2015      NCTpembrolizumab 2mgdocetaxel2L, PD-L1 positive 2nd+ line Risk of bias suggesting
Keynote 042 (>=1%), 2018    NCTpembrolizumabplatinum-based CT1L, PDL1 positive 1st line PD-L1 positive Risk of bias suggesting
Keynote 024, 2015      NCTpembrolizumabplatinum-based CT1L, PDL1 positive 1st line PD-L1 positive Risk of bias suggesting
Keynote 042 (>=50%), 2018    NCTpembrolizumabplatinum-based CT1L, PDL1 positive 1st line PD-L1 positive Risk of bias suggesting
Keynote 042 (>=20%), 2018    NCTpembrolizumabplatinum-based CT1L, PDL1 positive 1st line PD-L1 positive Risk of bias suggesting
KEYNOTE-021 phase 2, 2016      NCTpembrolizumab + platinum-based CTplatinum-based CT1L nonsquamous 1st line nonsquamous NSCLC Exploratory suggesting
Keynote 189, 2018      NCTpembrolizumab + platinum-based CTplatinum-based CT1L PD-L1 positive nonsquamous 1st line nonsquamous NSCLC Low risk of bias conclusive
Keynote 407, 2018    NCTpembrolizumanb + CTplatinum-based CT1L squamous squamous NSCLC Risk of bias suggesting

Taxanes

not classified
Herbst     suggesting
Gebbia      -
Pectasides     suggesting
Takeda     suggesting
Pallis     suggesting
Heymach      -
Wachters     negative
Segawa   -
TAX 320 75mg/m2, 2000     docetaxel D75 -
TAX 317 (Shepherd) 75mg/m2, 2000     docetaxel D75 -
docetaxel
TAX 317 (Shepherd) 100mg/m2, 2000       docetaxel -
TAX 320 100mg/m2, 2000     docetaxel -
DISTAl 01 (Gridelli) , 2004     weekly docetaxel3-weekly docetaxel -
Camps     weekly docetaxel3-weekly docetaxel -
Schuette     weekly docetaxel3-weekly docetaxel -
Gervais     weekly docetaxel3-weekly docetaxel -
Lai     weekly docetaxel3-weekly docetaxel -
Chen     weekly docetaxel3-weekly docetaxel -
Esteban, 2003     paclitaxel 80mg/m2m2docetaxel 36 mg/ -